Literature DB >> 28379894

Current Practice of Therapeutic Drug Monitoring of Biopharmaceuticals in Psoriasis Patients.

Caroline Hermans1, Pedro Herranz, Siegfried Segaert, Ann Gils.   

Abstract

The high prevalence of psoriasis and the high spending on pharmaceuticals motivate a more evidence-based and cost-effective usage of biopharmaceuticals. A growing body of evidence exists that the implementation of therapeutic drug monitoring for biopharmaceuticals in psoriasis patients optimizes patient management and clinical outcome and enhances their efficacy. Therefore, the aim of this review was to give an overview of the literature on therapeutic drug monitoring of biopharmaceuticals in the treatment of psoriasis and to provide the useful information to dermatologists to improve health care in psoriasis patients.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28379894     DOI: 10.1097/FTD.0000000000000401

Source DB:  PubMed          Journal:  Ther Drug Monit        ISSN: 0163-4356            Impact factor:   3.681


  3 in total

Review 1.  Practical recommendations for the use of therapeutic drug monitoring of biopharmaceuticals in inflammatory diseases.

Authors:  Erwin Dreesen; Peter Bossuyt; Denis Mulleman; Ann Gils; Dora Pascual-Salcedo
Journal:  Clin Pharmacol       Date:  2017-10-03

2.  Clinical response correlates with 4-week postinjection ustekinumab concentrations in patients with moderate-to-severe psoriasis.

Authors:  N Van den Berghe; E De Keyser; R Soenen; L Meuleman; S Lanssens; A Gils; J Lambert
Journal:  Br J Dermatol       Date:  2019-07-24       Impact factor: 9.302

Review 3.  The Evolving Role of Microsampling in Therapeutic Drug Monitoring of Monoclonal Antibodies in Inflammatory Diseases.

Authors:  Panagiotis-Dimitrios Mingas; Jurij Zdovc; Iztok Grabnar; Tomaž Vovk
Journal:  Molecules       Date:  2021-03-22       Impact factor: 4.411

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.